Oct 19 (Reuters) - Amgen Inc: * AMGEN: BEMARITUZUMAB (BEMA) DEMONSTRATED STATISTICALLY SIGNIFICANT SURVIVAL BENEFIT AT PRIMARY ANALYSIS OF FORTITUDE-101 PHASE 3 TRIAL Source text: Further company coverage: (The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
